Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Shares Sold by Fmr LLC

Fmr LLC lowered its stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 6.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,479,235 shares of the company’s stock after selling 159,159 shares during the period. Fmr LLC’s holdings in Maravai LifeSciences were worth $20,602,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. GAMMA Investing LLC raised its holdings in shares of Maravai LifeSciences by 310.2% in the second quarter. GAMMA Investing LLC now owns 3,585 shares of the company’s stock worth $26,000 after acquiring an additional 2,711 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Maravai LifeSciences in the 2nd quarter worth about $32,000. Blue Trust Inc. acquired a new position in shares of Maravai LifeSciences in the 2nd quarter valued at about $44,000. Venturi Wealth Management LLC purchased a new stake in shares of Maravai LifeSciences during the 3rd quarter worth about $47,000. Finally, Custom Index Systems LLC acquired a new stake in Maravai LifeSciences during the 3rd quarter worth approximately $97,000. Hedge funds and other institutional investors own 50.25% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. William Blair reaffirmed a “market perform” rating on shares of Maravai LifeSciences in a research report on Friday, November 8th. Wells Fargo & Company began coverage on shares of Maravai LifeSciences in a research report on Tuesday, August 27th. They set an “overweight” rating and a $10.00 price target for the company. Morgan Stanley lowered Maravai LifeSciences from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $11.00 to $10.00 in a research report on Tuesday, August 13th. The Goldman Sachs Group downgraded Maravai LifeSciences from a “neutral” rating to a “sell” rating and decreased their target price for the stock from $7.00 to $4.25 in a research report on Thursday, December 5th. Finally, Robert W. Baird dropped their target price on Maravai LifeSciences from $10.00 to $9.00 and set an “outperform” rating on the stock in a report on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, Maravai LifeSciences has an average rating of “Hold” and an average price target of $10.03.

Insider Buying and Selling at Maravai LifeSciences

In related news, insider Carl Hull bought 175,000 shares of the business’s stock in a transaction dated Monday, November 11th. The shares were acquired at an average price of $5.64 per share, for a total transaction of $987,000.00. Following the purchase, the insider now owns 175,000 shares in the company, valued at $987,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.63% of the stock is currently owned by corporate insiders.

Maravai LifeSciences Trading Up 7.5 %

Shares of MRVI opened at $5.43 on Tuesday. Maravai LifeSciences Holdings, Inc. has a one year low of $4.28 and a one year high of $11.56. The stock has a 50-day moving average price of $6.74 and a 200 day moving average price of $7.90. The company has a debt-to-equity ratio of 0.89, a quick ratio of 9.94 and a current ratio of 10.74. The company has a market capitalization of $1.37 billion, a P/E ratio of -3.31 and a beta of -0.08.

Maravai LifeSciences Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.